4DR	4-class Drug Resistance
4DR-PWH	People with HIV with 4-class Drug Resistance
ART	Antiretroviral Therapy
ARV	Antiretroviral
BIC	Bictegravir
CD4+	CD4-positive T lymphocytes
CI	Confidence Interval
DDI	Drug–Drug Interaction
DODA	Dual therapy with Dolutegravir plus boosted Darunavir
DODA + Other	Dolutegravir plus boosted Darunavir with ≥1 additional ARV
DRV/b	Boosted Darunavir (Darunavir co-administered with ritonavir or cobicistat)
DTG	Dolutegravir
EVG	Elvitegravir
GRT	Genotypic Resistance Testing
GSS	Genotypic Susceptibility Score
HTE	Heavily Treatment-Experienced
INSTI	Integrase Strand Transfer Inhibitor
IQR	Interquartile Range
NO-DODA	Regimens excluding the DTG + DRV/b combination
PWH	People with HIV
RAL	Raltegravir
VF	Virological Failure